These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21676958)

  • 1. A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
    Delbeck M; Nickel KF; Perzborn E; Ellinghaus P; Strassburger J; Kast R; Laux V; Schäfer S; Schermuly RT; von Degenfeld G
    Cardiovasc Res; 2011 Oct; 92(1):159-68. PubMed ID: 21676958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
    Porvasnik SL; Germain S; Embury J; Gannon KS; Jacques V; Murray J; Byrne BJ; Shacham S; Al-Mousily F
    J Pharmacol Exp Ther; 2010 Aug; 334(2):364-72. PubMed ID: 20430844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
    Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral rivaroxaban for symptomatic venous thromboembolism.
    ; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
    N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
    Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels.
    Shen L; Shen J; Pu J; He B
    Cell Biochem Biophys; 2011 Sep; 61(1):23-31. PubMed ID: 21327581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension.
    Homma N; Morio Y; Takahashi H; Yamamoto A; Suzuki T; Sato K; Muramatsu M; Fukuchi Y
    Respiration; 2006; 73(1):105-12. PubMed ID: 16432296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term administration of a cell-permeable caveolin-1 peptide prevents the development of monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy.
    Jasmin JF; Mercier I; Dupuis J; Tanowitz HB; Lisanti MP
    Circulation; 2006 Aug; 114(9):912-20. PubMed ID: 16940204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resveratrol inhibits right ventricular hypertrophy induced by monocrotaline in rats.
    Yang DL; Zhang HG; Xu YL; Gao YH; Yang XJ; Hao XQ; Li XH
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):150-5. PubMed ID: 19566840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
    Tofovic SP; Zhang X; Jackson EK; Dacic S; Petrusevska G
    Vascul Pharmacol; 2006 Dec; 45(6):358-67. PubMed ID: 16872912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Misselwitz F; Muehlhofer E; Kälebo P
    Thromb Res; 2007; 120(5):685-93. PubMed ID: 17292948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of various doses of monocrotaline administration on the development of pulmonary hypertension and its regression in rats].
    Kakusaka I; Kaneko N; Kiyatake K; Fujita A; Suzuki A; Nakano K; Okada O; Sugita T; Watanabe S; Kuriyama T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):51-6. PubMed ID: 2501548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
    Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
    Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
    Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats].
    Li XL; Guan RJ; Xu QH; Wu ZY
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Mar; 39(3):247-53. PubMed ID: 21609531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment.
    Mathew R; Altura BT; Altura BM
    Magnesium; 1989; 8(2):110-6. PubMed ID: 2526910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.
    Lu J; Shimpo H; Shimamoto A; Chong AJ; Hampton CR; Spring DJ; Yada M; Takao M; Onoda K; Yada I; Pohlman TH; Verrier ED
    J Thorac Cardiovasc Surg; 2004 Dec; 128(6):850-9. PubMed ID: 15573069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
    Laux V; Perzborn E; Kubitza D; Misselwitz F
    Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.